Therapeutic effects of CuII(atsm) in the SOD1-G37R mouse model of amyotrophic lateral sclerosis

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Volumn 14, Issue 7-8, 2013, Pages 586-590

  McAllum, Erin J ^a   Lim, Nastasia K H ^a   Hickey, James L ^b,c   Paterson, Brett M ^b,c   Donnelly, Paul S ^b,c   Li, Qiao Xin ^d   Liddell, Jeffrey R ^a   Barnham, Kevin J ^a,c,d   White, Anthony R ^a,d   Crouch, Peter J ^a,d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Particulate Fluids Processing Centre   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

Amyotrophic lateral sclerosis (ALS); Diacetylbis(4 methylthiosemicarbazone) copperII CuII(atsm) ; Riluzole; Rotarod; Therapeutic

Indexed keywords

COPPER; COPPER DIACETYLBIS(4 METHYLTHIOSEMICARBAZONE); COPPER ZINC SUPEROXIDE DISMUTASE; RILUZOLE; UNCLASSIFIED DRUG; COPPER (II) DIACETYL DI(N(4) METHYLTHIOSEMICARBAZONE); COPPER (II) DIACETYL-DI(N(4)-METHYLTHIOSEMICARBAZONE); ORGANOMETALLIC COMPOUND; SOD1 G37R PROTEIN, MOUSE; SUPEROXIDE DISMUTASE; THIOSEMICARBAZONE DERIVATIVE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GENE MUTATION; LOCOMOTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; DISEASE MODEL; DOSE RESPONSE; ENZYMOLOGY; FEMALE; GENETICS; HUMAN; MALE; RANDOMIZATION; TRANSGENIC MOUSE; TREATMENT OUTCOME;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; COPPER; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MICE; MICE, TRANSGENIC; ORGANOMETALLIC COMPOUNDS; RANDOM ALLOCATION; SUPEROXIDE DISMUTASE; THIOSEMICARBAZONES; TREATMENT OUTCOME;

EID: 84887471411     PISSN: 21678421     EISSN: 21679223     Source Type: Journal    
DOI: 10.3109/21678421.2013.824000     Document Type: Article

References (14)

1. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994; 330:585-91.
2. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996; 347:1425-31.
3. Soon C P, Donnelly P S, Turner B J, Hung L W, Crouch P J, Sherratt NA, et al. Diacetylbis(N(4)-methylthiosemicarbazonato) copper(II) (CuII(atsm)) protects against peroxynitrite-induced nitrosative damage and prolongs survival in amyotrophic lateral sclerosis mouse model. J Biol Chem. 2011; 286:44035-44.
4. Fodero-Tavoletti M T, Villemagne V L, Paterson BM, White AR, Li QX, Camakaris J, et al. Bis(thiosemicarbazonato) Cu-64 complexes for positron emission tomography imaging of Alzheimer's disease. J Alzheimers Dis. 2010; 20:49-55.
5. Hung L W, Villemagne V L, Cheng L, Sherratt N A, Ayton S, White AR, et al. The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease. The Journal of Experimental Medicine. 2012; 209:837-54.
6. Wong P C, Pardo CA, Borchelt DR, Lee MK, Copeland NG, Jenkins NA, et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron. 1995; 14:1105-16.
7. Blower PJ, Castle TC, Cowley A R, Dilworth JR, Donnelly PS, Labisbal E, et al. Structural trends in copper(II) bis (thiosemicarbazone) radiopharmaceuticals. Dalton Transactions. 2003; 4416-25.
8. Gingras BA, Suprunchuk T, Bayley CH. The preparation of some thiosemicarbazones and their copper complexes: Part III. Canadian Journal of Chemistry. 1962; 40:1053-9.
9. Padi P, Ganta M, Bollikonda S, Chaganti S, Akula R, Dommati L. Process for preparing riluzole. 2008. US 20080108827. United States of America.
10. Gurney ME, Cutting FB, Zhai P, Doble A, Taylor CP, Andrus PK, et al. Benefi t of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol. 1996; 39:147-57.
11. Gurney M E, Fleck T J, Himes C S, Hall E D. R iluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology. 1998; 50:62-6.
12. Snow RJ, Turnbull J, da Silva S, Jiang F, Tarnopolsky MA. Creatine supplementation and riluzole treatment provide similar benefi cial effects in copper/zinc superoxide dismutase (G93A) transgenic mice. Neuroscience. 2003; 119:661-7.
13. Waibel S, Reuter A, Malessa S, Blaugrund E, Ludolph AC. Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. J Neurol. 2004; 251:1080-4.
14. Crow J P, Calingasan N Y, Chen J, Hill J L, Beal M F. M anganese porphyrin given at symptom onset markedly extends survival of ALS mice. Ann Neurol. 2005; 58:258-65.